Steady-state kinetics of 5-aminosalicylic acid and sulfapyridine during sulfasalazine prophylaxis in ulcerative colitis.
Fifteen adult and 19 pediatric outpatients with ulcerative colitis were studied to determine the steady-state kinetics of 5-aminosalicylic acid (5-ASA) released from salazosulfapyridine (SASP). Results of excretion in adults (mean 24-h recovery of 5-ASA, 21% in urine and 57% in feces) were compatible with those of healthy volunteers. Since mean SASP dose/kg body weight (about 50 mg/kg) and compliance (reflected in sulfapyridine recovery) were equal in adults and pediatric patients, the results of the patient groups could be compared. Near-complete azo reduction of SASP occurs in children. Absorption and excretion of 5-ASA and metabolism to acetyl-5-ASA did not differ statistically between pediatric and adult patients. However, the fecal excretion of the drug and its metabolites was significantly lower in young patients, although fecal concentrations were the same. The present results demonstrate that SASP is an excellent sustained-release drug for the delivery of 5-ASA to the lower part of the bowel system and provide a reference for comparison of 5-ASA kinetics after treatment with newer 5-ASA preparations.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000636:Aminosalicylic Acids / Q000378:metabolism*; D003093:Colitis, Ulcerative / Q000188:drug therapy* / Q000378:metabolism; D005260:Female; D006801:Humans; D007700:Kinetics; D008297:Male; D019804:Mesalamine; D008875:Middle Aged; D013424:Sulfanilamides / Q000378:metabolism*; D013427:Sulfapyridine / Q000378:metabolism*; D012460:Sulfasalazine / Q000378:metabolism* / Q000627:therapeutic use
D000636:Aminosalicylic Acids; D013424:Sulfanilamides; D012460:Sulfasalazine; D019804:Mesalamine; D013427:Sulfapyridine